
This analysis demonstrated significant variability in medical policy determinations and evidence cited for clinically relevant pharmacogenetic tests among major US health insurers and laboratory benefit managers.
This analysis demonstrated significant variability in medical policy determinations and evidence cited for clinically relevant pharmacogenetic tests among major US health insurers and laboratory benefit managers.
This retrospective cohort study in a Medicare Advantage population posits that type 2 diabetes mellitus complications pose an excess burden on healthcare resource use and related costs.
Published: August 18th 2025 | Updated: August 25th 2025
Published: August 19th 2025 | Updated: August 22nd 2025
Published: June 6th 2025 | Updated: August 18th 2025
Published: June 27th 2025 | Updated: July 1st 2025
Published: February 20th 2025 | Updated: February 21st 2025
Published: January 16th 2025 | Updated: January 29th 2025
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.